Toxicologic study of carboxyatractyloside (active principle in cocklebur--Xanthium strumarium) in rats treated with enzyme inducers and inhibitors and glutathione precursor and depletor.
Male rats (10 rats/group) were treated with phenobarbital (PB), phenylbutazone (PBZ), stanozolol (3 inducers of cytochrome P450-dependent enzymes), piperonyl butoxide (PBO; a P450 inhibitor), cobaltous chloride (CoCl2; an inhibitor of hemoprotein synthesis), 5,6-benzoflavone (BNF; an inducer of cytochrome P448 dependent enzymes), cysteine [CYS; a glutathione (GSH) precursor], or ethyl maleate (EM; a GSH depletor). The rats were then given a calculated LD50 dosage (13.5 mg/kg of body weight) of carboxyatractyloside (CAT) intraperitoneally. Clinical signs of toxicosis, duration of illness, lethality, gross lesions, and hepatic and renal histopathologic lesions were recorded. Seemingly, (i) CAT toxicosis has independent lethal and cytotoxic components (PBZ decreased lethality and cytotoxicity; CoCl2 decreased cytotoxicity but not lethality; BNF decreased duration of illness, and perhaps lethality, but not cytotoxicity); (ii) CAT cytotoxicity could be partly due to an active metabolite formed by de novo-synthesized, P450-/P448-independent hemoprotein (PBZ and CoCl2 had anticytotoxic effects, but PB, stanozolol, PBO, and BNF did not); (iii) CAT detoxification may occur partly through a hemoprotein-independent, PBZ-inducible enzyme, and partly through a P448-dependent (BNF-inducible) enzyme; and (iv) CAT detoxification apparently is not P450 or GSH-dependent because PB, stanozolol, and CYS had no beneficial effects, and PBO, CoCl2, and EM did not enhance toxicosis. Metabolism of CAT may have a role in its cytotoxic and lethal effects.
D000818:Animals; D001278:Atractyloside / Q000031:analogs & derivatives / Q000506:poisoning*; D001571:Benzoflavones / Q000627:therapeutic use; D003035:Cobalt / Q000627:therapeutic use; D003545:Cysteine / Q000627:therapeutic use; D006027:Glycosides / Q000506:poisoning*; D007684:Kidney Tubules / Q000473:pathology; D007928:Lethal Dose 50; D008099:Liver / Q000473:pathology; D008297:Male; D008298:Maleates / Q000627:therapeutic use; D010634:Phenobarbital / Q000627:therapeutic use; D010653:Phenylbutazone / Q000627:therapeutic use; D010882:Piperonyl Butoxide / Q000627:therapeutic use; D010947:Plants, Toxic; D051381:Rats; D011919:Rats, Inbred Strains; D013197:Stanozolol / Q000627:therapeutic use; D019324:beta-Naphthoflavone
D001571:Benzoflavones; D006027:Glycosides; D008298:Maleates; D001278:Atractyloside; D003035:Cobalt; D013197:Stanozolol; D019324:beta-Naphthoflavone; C018021:cobaltous chloride; C014476:diethyl maleate; D010653:Phenylbutazone; D003545:Cysteine; D010882:Piperonyl Butoxide; C003853:carboxyatractyloside; D010634:Phenobarbital